INNOVATE announced that MediBeacon, a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, has received approval from the National Medical Products Administration for Lumitrace injection, a non-radioactive, non-iodinated fluorescent GFR agent. Lumitrace will be sold as an integral component of the Transdermal GFR System in China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VATE: